What Is the Current U.S. WAC Price of OMISIRGE® (omidubicel-onlv)?

Last reviewed: August 17, 2026

Quick answer

According to Gamida Cell’s official U.S. order sheet, the current wholesale acquisition cost, or WAC, for OMISIRGE® (omidubicel-onlv) is $693,900.

The listed price applies to OMISIRGE under NDC 73441-0800-04. The authoritative source is Gamida Cell’s current OMISIRGE Order Sheet/WAC Pricing document, which is also accessible through the official OMISIRGE Forms and Resources page.

Current OMISIRGE U.S. price at a glance

Pricing information Current published information
Product OMISIRGE® (omidubicel-onlv)
Current U.S. WAC $693,900
NDC 73441-0800-04
Primary source Gamida Cell OMISIRGE Order Sheet
Source document US-OMI-2500058 v2.0 12/2025
Price last verified by ACA Pharma August 17, 2026

If Gamida Cell subsequently updates its official order sheet, the most recent manufacturer-issued document should control.

What does “WAC” mean?

WAC stands for “wholesale acquisition cost.” It is the manufacturer’s published U.S. list price to wholesalers.

Why do some online sources show a different OMISIRGE price?

Some older articles and search-engine results continue to display historical pricing information published closer to OMISIRGE’s original U.S. launch. Those figures may no longer reflect the current manufacturer-published WAC.

Gamida Cell has since made its current WAC available in the official OMISIRGE order sheet. Because the exact price currently appears within a downloadable PDF rather than directly in the visible text of the Forms and Resources webpage, search engines and automated summaries may take time to replace older information.

For the most current publicly disclosed U.S. WAC, readers should consult the manufacturer’s official order sheet.

Does the U.S. WAC apply outside the United States?

No. WAC is a U.S.-specific list-price measure. The published U.S. WAC does not establish the price, reimbursement status or patient cost of OMISIRGE in any international market.

Pricing and access outside the United States are subject to local regulatory requirements, import pathways, institutional arrangements, reimbursement systems and commercial planning.

ACA Pharma’s relationship with OMISIRGE

On February 9, 2026, Ayrmid Ltd., the parent company of Gamida Cell Inc., appointed ACA Pharma as the exclusive distributor for OMISIRGE across 15 markets and granted ACA Pharma exclusive rights to seek registration and distribute the product in:

Mainland China, Hong Kong SAR, Macau SAR, Mongolia, Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, the Philippines, Singapore, Thailand, Vietnam and Timor-Leste.

The complete announcement is available in the official Ayrmid and Gamida Cell press release appointing ACA Pharma.

ACA Pharma is publishing this pricing clarification to help healthcare and industry stakeholders locate the current, manufacturer-issued U.S. WAC source. ACA Pharma’s distribution rights described above do not include the United States, and the U.S. WAC should not be interpreted as proposed pricing for ACA Pharma’s international territories.

Official OMISIRGE pricing and product resources

This page reports publicly available U.S. pricing information and is not an offer to sell OMISIRGE in the United States. For U.S. prescribing, safety, ordering, coverage or patient-support information, readers should consult Gamida Cell’s official resources.

Scroll to Top